Assessing pattern of the Pediatric Multisystem Inflammatory Syndrome (PMIS) in children during the COVID-19 pandemic: experience from the emergency department of tertiary care center of a low-middle-income country

The 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2) is a viral pandemic that spread worldwide. During the early phase of the COVID-19 pandemic, children were thought to be less affected, with mild respiratory symptoms and low morbidity and mortality [1, 2]. As the pandemic progressed, several studies reported severe complications in children with features of significant inflammation, toxic shock syndrome, and clinical features similar to incomplete Kawasaki Disease (KD) [3]. In particular, a syndrome of hyperinflammatory process associated with fever emerged in the pediatric population with positive COVID-19 test results [4]. The syndrome was later described as Pediatric Inflammatory Multisystem Syndrome (PMIS) by the Royal College of Pediatrics and Child Health (RCPCH) and as Multisystem Inflammatory Syndrome in Children (MIS-C) by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) [5‐7]. PMIS or MISC was preliminarily defined as a hyperinflammatory syndrome with multiorgan involvement and clinical features that overlap with KD [8].

The cases of this hyperinflammatory syndrome have similarities to KD and Toxic Shock Syndrome (TSS) [9]. Several cases have been reported from the emergency department (ED) with shock and multiorgan failure. However significant data is lacking, especially from the emergency departments (EDs) of low-middle-income countries (LMIC) [10]. This study was conducted in an ED of a tertiary care hospital in a low-middle-income country to fulfill this research gap. This study aims to determine the frequency, pattern of presentations, and laboratory parameters in children presenting with Pediatric Multisystem Inflammatory Syndrome (PMIS) to ED during the COVID-19 pandemic.

A total of 56 patients were diagnosed with PMIS. The mean age of the patients was 7.67 ± 4.8 years, ranging from 1 month to 16 years. Notably, all age groups, encompassing infants, children, and adolescents, were affected with equal frequency. Our study exhibited a distinct male predominance, accounting for 85.7% of the cases. A comprehensive depiction of patients’ demographics and baseline characteristics is available in Table 1.

The chief presenting complaints encompassed respiratory, neurological, gastrointestinal, and dermatological manifestations. Clinical assessments revealed prevalent signs including delayed capillary refill time (93%), low volume pulses (89%), hypotension (68%), and tachycardia (60%). Further details regarding presenting complaints and examination findings are outlined in Table 2.

Our screening protocol involved COVID-19 evaluation for all 56 patients. Initially, a COVID-19 PCR test was conducted, followed by COVID-19 antibodies if PCR yielded negative results. Interestingly, COVID-19 PCR testing yielded positive results in only 18% (10) of the patients, whereas COVID-19 antibodies were detected in 78.6% (44). Among the 12 patients with negative COVID-19 antibodies, 83.3% (10) tested PCR positive, with a mere 16.7% (2) displaying both negative antibodies and PCR results.

Hematological, inflammatory biomarkers and biochemical parameters were assessed, and their descriptive characteristics are presented in Table 3. Comprehensive cardiac evaluations, inclusive of Electrocardiography (ECG), Troponin, N-type Pro BNP, and Transthoracic Echocardiography, were performed for all patients. Sinus tachycardia with non-specific ST-T changes dominated ECG findings (91%), with only a minimal percentage exhibiting ventricular tachycardia (2%), supraventricular tachycardia (4%), or a normal sinus rhythm (4%).

Echocardiography results showcased a spectrum of left ventricular systolic dysfunction: 55% exhibited normal function, while 45% displayed variable degrees of dysfunction. Troponin elevation was noted in 70% of patients, with a raised N-type Pro BNP level observed in 78% of cases.

Therapeutically, 78–85% of patients received Intravenous Immunoglobulin (IVIG) and methylprednisolone as anti-inflammatory agents. Epinephrine was administered solely to 68% of patients for inotropic support, while the remaining individuals received a combination of Epinephrine with either Milrinone or Norepinephrine infusion. Respiratory assistance was requisite for 75% of patients, with 41% employing non-invasive methods like High Flow Nasal Cannula (HFNC), and 35% necessitating invasive interventions such as endotracheal intubation and mechanical ventilation.

The multivariate binary regression model unveiled several notable risk factors linked to mortality. These findings are summarized in Table 4.

Initially, COVID-19 in children appeared mild. However, a subset of cases exhibited severe inflammation and multi-organ problems, leading to Pediatric Inflammatory Multisystem Syndrome (PMIS), or Multisystem Inflammatory Syndrome in Children (MIS-C). This study investigates the frequency, presentation, and lab findings in PMIS cases among children, offering scientific insights into this condition.

In this study, we examined 56 pediatric patients diagnosed with Pediatric Inflammatory Multisystem Syndrome (PMIS) in the emergency department (ED) at Aga Khan University Hospital (AKUH), Pakistan. Notably, our study highlights several key findings. We observed a gender and age distribution in PMIS cases that differs from previous reports. Our cohort had a higher mean age (7.67 years) compared to studies from Latin America, France, and Switzerland. Males represented most cases (85%), aligning with existing literature suggesting gender-associated risk factors [13‐16].

Our study revealed differences in clinical presentation compared to studies in other regions. Most of our patients presented with respiratory complaints (70%), followed by neurological symptoms (57%). In contrast, studies from the U.S. reported gastrointestinal symptoms (80%) and cardiovascular issues, including echocardiographic anomalies and hypotension (63%). Regardless of the region, a significant proportion of PMIS cases required intensive care [14].

Interestingly, gastrointestinal complaints were notably prevalent in the group of patients who did not survive in our sample. In our cohort, respiratory complaints dominated as the most frequent patient grievance, followed by neurological issues. This diverges from a U.S. study encompassing 26 states, wherein gastrointestinal involvement was reported in 92% of cases, whereas respiratory symptoms accounted for 70% of the sample. Another systematic review of MIS-C outlined that 4 out of 5 cases exhibited diarrhea and abdominal pain, at times severe enough to mimic appendicitis. This might be attributed to SARS-CoV-2’s mode of transmission, impacting angiotensin-converting enzyme receptors (ACE receptors) prevalent in the gastrointestinal tract [23]. Given children’s underdeveloped hand hygiene habits and relatively immature immune systems, it’s plausible that gastrointestinal symptoms are more pronounced, particularly as the virus establishes itself in the body after clearing from the upper respiratory tract [21].

All patients in our study underwent COVID screening, with most displaying positive serology results, alongside some showing positive PCR outcomes. This aligns with the fact that PMIS typically manifests weeks after the active viral infection, rendering PCR positivity obsolete and antibodies crucial. This trend supports the hypothesis that PMIS could stem from the immune response against the virus, potentially triggering a cytokine storm and culminating in hyperinflammation. Severe cases might involve antibody-dependent enhancement, where certain antibodies fail to neutralize the virus, inadvertently facilitating its propagation [25, 13].

The majority of our study cohort presented with abnormal ECG readings, a hallmark of myocarditis due to its frequent association with sinus tachycardia, a common finding in myocarditis. Multiple studies have highlighted the connection between COVID-19 and myocarditis-like symptoms, often characterized by arrhythmias [26, 24]. Similarly, our findings emphasized sinus tachycardia, accompanied by ventricular tachycardia, implicating cardiac involvement. Consequently, most patients demonstrated delayed capillary refill time and required cardiac resynchronization therapy in under 2 s.

Notably, inflammatory markers indicative of cardiac injury, such as ESR, ferritin, LDH, fibrinogen, and CRP levels, were elevated in patients fulfilling PMIS criteria [26]. This corresponds to the underlying pathogenesis, wherein our study observed elevated LDH, Ferriten, D-dimer, and Pro-BNP levels associated with a higher risk of mortality. Particularly, patients with LDH levels exceeding a certain threshold displayed a pronounced association with the group of patients who did not survive [25]. Although the number of fatalities post-admission to the ED remained low in our sample [18, 19]. All patients were admitted to the Pediatric intensive care unit, required vasopressors, non-invasive and some required invasive mechanical ventilation [17]. As far as immunosuppressive therapy is concerned, the majority were treated with steroids and intravenous immunoglobulin. This is consistent with the studies by Belhadjer Z et al. who have reported the use of immunoglobulin in all their patients while adjunctive steroids were used in 3rd of their patient population [11].

It’s important to acknowledge the limitations of our study. The data exclusively originated from within AKUH, thereby constraining the sample size. Our data collection and analysis methods omitted geographical and sociocultural diversity comparisons. Moreover, the diagnosis of COVID-19 relied solely on throat PCR, as alternative methods like stool PCR were unavailable within our facilities. This approach, while valuable for detecting SARS-CoV-2 after clearance from the upper respiratory tract, has its limitations.

In summary, our study adds to the growing body of knowledge concerning PMIS in pediatric populations, offering insights into its prevalence, presentation, and laboratory profiles. By examining cases in a developing country like Pakistan, we contribute to a more comprehensive understanding of this complex condition and underscore the global significance of its clinical manifestations.

PMIS affects children of all ages, with a male predominance. Respiratory and gastrointestinal symptoms are the most frequent presentations.Myocarditis is the most common cardiac manifestation. Elevated inflammatory markers, including LDH, Ferritin, D-dimer, and Pro-BNP, correlate with higher mortality risk.

Our collective insights will guide clinical management and public health responses to PMIS in children during the ongoing pandemic. Further research across diverse settings will deepen our understanding and address the challenges posed by PMIS.